About us

At admedicum, Patient Engagement is our core business

We are experts in designing, enabling and executing patient-focused activities in daily practice

admedicum was established in 2016 with Expert Partners

We are currently operating in Portugal, Spain, Italy, Germany, France, United Kingdom, the Netherlands, and Belgium. Services are provided by our extended partner network in Ireland, the Nordics, Poland, Greece, South-East Europe, Austria, Switzerland, and the USA.
admedicum team members have the credibility, expertise, skills and experience to represent both the patient and industry perspective. We have worked on the patient side and in pharma and medtech industry positions. We understand patients and caregivers. And we understand industry.

Dr. Andreas L.G. Reimann

Managing Partner & Co-Founder

Social entrepreneur in the fields of patient-oriented health care and inclusive education. He studied pharmacy, was state-registered as a pharmacist and earned a PhD in Pharmacology.

Philipp von Gallwitz

Managing Partner & Co-Founder

Philipp worked 20 years in pharma industry and worked closely with patients for a variety of purposes. He is a passionate advocate of patient engagement.

Dr. Roger Legtenberg

Senior Partner & Co-Owner

Roger strongly believes that a change in business eco-system is required in order to address one of the most important challenges for the Life Sciences industry: the sustainability & society acceptance of development of new treatments for patients.

Ulrike Nowak

Director Patient Engagement and Head of Operations

Ulrike is a doctor’s assistant with over 8 years of experience in the fields of cardiology, general and internal medicine and surgery. She graduated with honors in health care management.

Dr. Meike Neukirchen

International Patient Engagement Manager

Dr. Meike Neukirchen is a licensed phamacist with more than 12 years experience in pharmaceutical industry.

Dr. Vera Vennedey

International Patient Engagement Manager

Vera holds a PhD in Health Sciences. She has in depth knowledge and practical experience in patient engagement in medical decision making, especially through patient preference analysis.

Marina Hoffmann

International Senior Patient Engagement Manager

Marina Hoffmann is a psychologist with more than 5 years of experience in the healthcare sector.

Christian Hoenig

Director Patient Engagement

Christian provides a very solid understanding and experience regarding the german pricing and reimbursement system to the team, including the importance of patient relevance data

Robert Pleticha

International Senior Patient Engagement Manager and Head of admedicum Spain

Robert is a patient advocate that has worked across four different EU countries. He is skilled at uniting international rare disease patient groups to address common goals.

Razak Ellafi

International Patient Engagement Manager and Head of admedicum France

Razak brings a strong background in digital and social innovation and public policy to the development of patient engagement.

Aileen Singhof, M.A.

Patient Engagement Consultant - Content Manager

Aileen Singhof has a Master’s degree in German literature and media.

Rainer Herzog

Digital Innovation Lead

Rainer Herzog is a well-versed executive in the healthcare industry, drawing on a long history of international experience.

Pierce Pizinger

Office Manager

Pierce Pizinger is responsible for general office organization and takes over administrative activities as well as operational accounting.

Saskia Zavelberg, M.Sc.

Patient Engagement Consultant

Saskia acquired a broad medical know-how through her international biomedical studies ( B.Sc. “Applied Life Sciences” & Ms.Sc. “Biomedical Engineering”).

Sheila Khawaja

Patient Expert Partner, Italy

Expert at admedicum, is based in Trieste, Italy.

Trishna Bharadia

Patient Expert Partner, UK

Many years of advocacy and patient engagement experience with industry, healthcare systems, healthcare professionals, patient organisations, academic institutions and charities.

Frank Hennemann

Patient Expert Partner, Germany

Frank has 48 years experience as a patient with a rare and deadly genetic disease called “Alpha1 Antrypsin Deficiency”

Nancy Meyerson-Hess, B.A., M.Phil.

Expert Partner and Quality Management

Nancy Meyerson-Hess has over 30 years of experience in clinical research. She has led global teams of clinical research professionals within pharmaceutical and …

Dagmar Mekking

Expert Partner

Dagmar is accredited and experienced in various leadership interventions and coaching methodologies, which are powerful tools to unleash the power of patient organizations as well as tapping into the full potential of leaders and employees in a pharmaceutical company.


How we help our clients


Faster clinical trial recruitment and higher retention rates and involving patient experts in the trial design and execution


Co-create patient-reported outcomes and real-world evidence that demonstrate the actual impact on patient’s life beyond clinical data points


Communicate patient-relevant added-value to Health-Technology Assessors credibly and based on the voice of the patients.


Establish a competitive advantage with regulatory authorities and payers through the design and execution of truly patient oriented products and services


Through our existing, strong networks and relationships with the European patient community – both with individual patient advocates and the organisations that represent them


We create value by making meaningful patient-access

We create value by making meaningful patient-access to our clients’ products and services possible. We achieve this by bringing patients and companies together at the right time and the right place. This way patients benefit by accessing innovative and truly patient oriented products and services. And companies increase their chance for return on investment.



"I clearly recommend admedicum’s services"

“We embraced admedicum’s services, in collaboration with Trials24, only by the time that we became aware that the inclusion of patients with certain hematologic malignancies in an ongoing phase I study of a PRAME-specific TCR-T was not as expected due to the very restrictive nature of the eligibility criteria. The admedicum team’s experience and creativity towards a fruitful approach to our reality of clinical study conduct within Germany clearly translated in a gateway towards potentially eligible patients, whom, upon a triage, could ultimately be guided in contacting the investigational sites. In concerto, a dedicated website for the specific conditions, use of advertising on social media and local radio presentation by clinical experts and the principal investigator did land a high number of patients or their caregivers to undergo the initial web-based triage towards an improved patient recruitment. Hence I clearly recommend admedicum’s services for clinical studies for which patient recruitment is expected to be difficult, ideally well before the start of the study.”

René Goedkoop MD,
Acting Chief Medical Officer, Medigene AG
"Many thanks to all of you for the great elaboration"
“Many thanks to all of you for the great elaboration of the project and the extensive exchange. I am still impressed that after the initial long questionnaire, which we worked out together over and over again, such a great final result was achieved and that this was only possible because many patients concerned had the opportunity to actively participate in the survey/discussion.”
Sabine Wagner,
Board member and regional group leader Network Neuroendocrine Tumors (NeT) e.V.
"Philipp's passion for patients needs is as admirable"

Philipp’s passion for patients’ needs and real innovation is as admirable as is his sharp intellect and his understanding of the science, providing for a blend of capabilities and attitude that make “business” equally enjoyable for colleagues and business partners. One always feels his determination to succeed, paired with the patience that our business needs, the preparedness and energy to deal with foreseeable and non-foreseeable hurdles keeping the motivation high at all times as a contributor to a project and as a leader.

Philipp’s vision of a patient centric approach to pharmaceutical development, in particular in rare and orphan diseases, together with the implementation of a concrete series of patient focused events has created a momentum that our company is still benefitting from.

Steffen Sturzebecher,
SVP head of innovation Unit Specialty Therapeutics, Grunenthal
"How much he cared about all people living with rare diseases is underpinned by his volunteer work"

“During his time as CEO of Mukoviszidose e.V., the German Cystic Fibrosis (CF) Association (2002 – 2014) and Managing Director of our research affiliate, Mukoviszidose Institut GmbH (2006 – 2015), I got to appreciate Andreas Reimann. I am a father of a son living with CF and I am grateful to what Andreas has contributed to the lives of CF-patients and their beloved ones.

Andreas could combine a human attitude and professionalism to the benefit of the patients. He helped to foster the association to an even higher reputation, both nationally and internationally. He managed to raise awareness in the public and fostered support in health-policy for the objectives of CF-patients. This again helped to bring CF into the focus of research and medical care. Thanks to his prudent financial management and his good relationship with major donors, the association could raise sufficient funds to foster research and therapy and to promote important international projects. Andreas always had an impact on patients and relatives in mind when making research and care a priority of our activities. He also encouraged patient activists in the association and co-operated with pharmaceutical companies on eye-level always keeping in mind that transparency and independence of the patient organisation must never be compromised with.

How much he cared about all people living with rare diseases is underpinned by his volunteer work as vice-president and later on as president of ACHSE, the German umbrella organisation for rare diseases.

If one day we manage to overcome CF, Dr. Reimann has contributed his share. He reminded decision-makers in Germany on their responsibility on the life of patients living with severe chronic diseases.”

Horst Mehl,
past-president and currently honorary president of Mukoviszidose e.V
"Philipp's skills, talents, and abilities are exactly what patient organizations need..."

“Philipp possesses all the many skills needed and essential for bringing together patient organizations and their KOLs into the limelight of industry! For more than 30 years, I have promoted genetic diseases and pain awareness as a health professional with a genetic diseases and chronic pain. I fully appreciate how crucial the needs for patient organizations and the mediation required by people like Philipp,  highly capable of collaborating, organizing, and following through, all essential to ensure the patient voice is heard, understood,  and brought directly to the industry. For three years, I witnessed Phillip’s commitment to patient organization collaborations. His skills, talents, and abilities are exactly what patient organizations need — and precisely what the industry requires,  to help bring  new ideas for treatment modalities into fruition.”

Susan Stephenson,
RN BSN CCRN Independent Rare Disease Pain Advocate and Consultant N. Chesterfield, VA USA
"This was truly the first patient-centric meeting I’ve ever attended, and that was very much thanks to Philipp‘s vision."

“The CDKL5 Research & Family conference, which Philipp was instrumental with in shaping the agenda, was an exceptionally great meeting! I had a chance to talk to many of the families and I know they appreciated these days and loved how much opportunity they had to participate and tell their stories and help shape the field and advance it. This was truly the first patient-centric meeting I’ve ever attended, and that was very much thanks to Philipp‘s vision.

Undisclosed pharma participant on the same conference: „You and Carol-Anne organized the best disease-focused family meeting I ever attended.  The interaction and co-collaboration amongst all constituents was extremely beneficial to everyone in attendance.  I especially appreciated hearing directly from the caregivers their needs and wants for clinical trials and new medications.”

Ana Mingorance,
Chief Development Officer LouLou Foundation, London, UK
"The DNSS experts were enthusiastic about the results and admedicum's competence"

“The Sklerodermie e.V. in connection with the scleroderma experts of the DNSS (German Network for Systemic Scleroderma) asked admedicum for support in conducting a survey among more than 1200 scleroderma patients in Germany. The aim was to investigate the extent to which scleroderma patients benefit from the infusion therapy, which is recommended but currently not refinanced and therefore difficult to obtain. The questionnaire developed by the Sklerodermie Selbsthilfe e.V. and experts in scleroderma was checked for plausibility by admedicum, supplemented, adapted, and prepared in such a way that it reached as many patients as possible in a short time, both on paper and via an online survey. admedicum did not only have considerable empathy and understood the problems and talked with us as if we would known each other already for years and let us feel that we were all on equal eye level.

The survey showed that a high percentage of patients benefit enormously from the therapy – medically and everyday life. “We finally had in our hands what we had known and experienced for years – but never in numbers and never according to different criteria could we question and evaluate.

The DNSS experts were enthusiastic about the results and admedicum’s competence and will prepare a scientific analysis on the basis of the survey, which without admedicum could not have been implemented in this way in terms of content, form or substance. This can be an important first step for the approval of the therapy and a cost assumption by the health insurance companies and thus an important step towards improved care of scleroderma patients.”

Emma Margarete Reil,
Chairman, Sklerodermie e.V.